Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Clinical Trials

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

The setback reduces near‑term prospects for the targeted antibody‑drug conjugate and shifts the program toward combination and earlier‑line studies.

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

Sacituzumab Tirumotecan With Keytruda Improves Progression-Free Survival in China Phase 3 Lung Cancer Trial

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Erasca Shares Plunge After Trial Death and Patent Challenge

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care